AR044940A1 - Compuestos heterociclicos y su uso como moduladores de gamma opioides - Google Patents
Compuestos heterociclicos y su uso como moduladores de gamma opioidesInfo
- Publication number
- AR044940A1 AR044940A1 ARP040102271A ARP040102271A AR044940A1 AR 044940 A1 AR044940 A1 AR 044940A1 AR P040102271 A ARP040102271 A AR P040102271A AR P040102271 A ARP040102271 A AR P040102271A AR 044940 A1 AR044940 A1 AR 044940A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkanyl
- quinolinyl
- amino
- group
- alkenyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 10
- 125000001424 substituent group Chemical group 0.000 abstract 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 3
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 3
- -1 phenylimino Chemical group 0.000 abstract 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000004428 fluoroalkoxy group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 1
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 abstract 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 108700023159 delta Opioid Receptors Proteins 0.000 abstract 1
- 102000048124 delta Opioid Receptors Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 abstract 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000001786 isothiazolyl group Chemical group 0.000 abstract 1
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 1
- RIFHJAODNHLCBH-UHFFFAOYSA-N methanethione Chemical group S=[CH] RIFHJAODNHLCBH-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 abstract 1
- 229940005483 opioid analgesics Drugs 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 125000005429 oxyalkyl group Chemical group 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se refiere a moduladores de receptores de delta opioides. En forma más específica, la presente se refiere a moduladores tricíclicos de delta-opioides. Se describen, además, composiciones de uso farmacéutico y veterinario y métodos de tratamiento del dolor leve a moderadamente grave y varias enfermedades que usan los compuestos de la presente. Reivindicación 1: Un compuesto de fórmula (1) en donde R1 y R2 son sustituyentes seleccionados en forma independiente del grupo formado por H y alcanilo C1-8; R3 se selecciona del grupo formado por H, alcanilo C1-8, halo 1-3alcanilo(C1-3), alquenilo C2-8, alquinilo C2-8, cicloalcanilo C3-8, cicloalcanil alcanilo (C1-8), alcanil C1-8 oxialcanilo (C1-8), alcaniltio C1-8 alcanilo(C1-8), hidroxialcanilo C1-8, alcaniloxicarbonilo C1-3, halo1-3 alcanil(C1-8) carbonilo, formilo, tioformilo, carbamimidoilo, fenilimino alcanilo (C1-8), fenilalcanilo (C1-8), fenilalquenilo (C1-8),fenilalquinilo (C1-8), naftilalcanilo C1-8 y heteoarilalcanilo (C1-8), donde el fenilo, naftilo y heteroarilo están sustituidos en forma opcional con 1 a 3 sustituyentes seleccionados en forma independiente del grupo formado por alcanilo C1-8, alquenilo C2-6, alcaniloxi C1-6, amino, alcanilamino C1-6, di(alcanil C1-6)amino, alcanil C1-6carbonilo, alcanil C1-6carboniloxi, alcanil C1-6carbonilamino, alcanil C1-6tio, alcanil C1-6sulfonilo, halógeno, hidroxi, ciano, fluoroalcanilo, tioureido, y fluoroalcaniloxi; en forma alternativa, cuando el fenilo y el heteroarilo están sustituidos en forma opcional con dos sustituyentes unidos a átomos de C adyacentes, los dos sustituyentes pueden formar, juntos, un único resto fusionado; donde el resto fusionado se selecciona del grupo formado por -(CH2)3-6- y -O(CH2)1-3O-; R4 es de 1 a 3 sustituyentes seleccionados en forma independiente del grupo formado por H, alcanilo C1-6, alquenilo C2-6, alcaniloxi C1-6, amino, alcanilamino C1-6, di(alcanil C1-6)amino, alcanil C1-6carbonilo, alcanil C1-6carboniloxi, alcanil C1-6oxicarbonilo, alcanil C1-6aminocarbonilo, di(alcanil C1-6)aminocarbonilo, alcanil C1-6carbonilamino, alcanil C1-6tio, alcanil C1-6sulfonilo, halógeno, hidroxi, ciano, hidroxicarbonilo, arilo C6-10, cromanilo, cromenilo, furanilo, imidazolilo, indazolilo, indolilo, indolinilo, isoindolinilo, isoquinolinilo, isotiazolilo, isoxazolilo, naftiridinilo, oxazolilo, pirazinilo, pirazolilo, piridazinilo, piridinilo, pirimidinilo, pirrolilo, quinazolinilo, quinolinilo, quinolizinilo, quinoxalinilo, tetrazolilo, tiazolilo, tiofenilo, fluoroalcanilo y fluoroalcaniloxi; o en forma opcional, cuando R4 es dos sustituyentes unidos a átomos de C adyacentes, los dos sustituyentes juntos forman un único resto fusionado; en el cual el resto fusionado se selecciona del grupo formado por -(CH2)3-5- y -O(CH2)1-2O-; R5 es de 1 a 2 sustituyentes seleccionados en forma independiente del grupo formado por H, alcanilo C1-6, alquenilo C2-6, alcanil C1-6oxi, amino, alcanil C1-6amino, di(alcanil C1-6)amino, alcanil C1-6carbonilo, alcanil C1-6carboniloxi, alcanil C1-6oxicarbonilo, alcanil C1-6aminocarbonilo, alcanil C1-6carbonilamino, alcanil C1-6tio, alcanil C1-6sulfonilo, halógeno, hidroxi, ciano, fluoroalcanilo y fluoroalcaniloxi; A es -(CH2)m, en el cual m es 0, 2 o 3; Y es -(CH2)nX- o -X(CH2)n; X es O ,o S, n es 0 o 1; Z es O o S; y sus enantiómeros, diastereómeros, tautómeros, solvatos o sales aceptables desde el punto de vista farmacéutico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48338903P | 2003-06-27 | 2003-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR044940A1 true AR044940A1 (es) | 2005-10-12 |
Family
ID=33563931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040102271A AR044940A1 (es) | 2003-06-27 | 2004-06-28 | Compuestos heterociclicos y su uso como moduladores de gamma opioides |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US7589103B2 (es) |
| EP (1) | EP1644373A1 (es) |
| JP (1) | JP4810423B2 (es) |
| KR (1) | KR101132208B1 (es) |
| CN (1) | CN100513407C (es) |
| AR (1) | AR044940A1 (es) |
| AU (1) | AU2004253898A1 (es) |
| BR (1) | BRPI0411998A (es) |
| CA (1) | CA2530444C (es) |
| CR (1) | CR8166A (es) |
| EA (1) | EA015491B1 (es) |
| EC (1) | ECSP056256A (es) |
| IL (1) | IL172713A0 (es) |
| NO (1) | NO333611B1 (es) |
| NZ (1) | NZ572901A (es) |
| TW (1) | TWI368510B (es) |
| UA (1) | UA86024C2 (es) |
| WO (1) | WO2005003131A1 (es) |
| ZA (1) | ZA200600770B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0300105D0 (sv) * | 2003-01-16 | 2003-01-16 | Astrazeneca Ab | Diarylmethylidene piperdine derivatives, preparations thereof and uses thereof |
| SE0300103D0 (sv) * | 2003-01-16 | 2003-01-16 | Astrazeneca Ab | Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof |
| WO2005003131A1 (en) | 2003-06-27 | 2005-01-13 | Janssen Pharmaceutica N.V. | Tricyclic delta opioid modulators |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| AU2005275181A1 (en) | 2004-07-14 | 2006-02-23 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| NZ553329A (en) | 2004-07-22 | 2010-09-30 | Ptc Therapeutics Inc | Thienopyridines for treating hepatitis C |
| CA2574768A1 (en) * | 2004-08-05 | 2006-02-05 | Janssen Pharmaceutica N.V. | Tricyclic delta-opioid modulators |
| AU2005319060A1 (en) * | 2004-12-22 | 2006-06-29 | Janssen Pharmaceutica N.V. | Tricyclic delta-opioid modulators |
| BRPI0519198A2 (pt) * | 2004-12-22 | 2008-12-30 | Janssen Pharmaceutica Nv | moduladores de delta-opiàide tricÍclicos |
| CA2592464A1 (en) * | 2004-12-22 | 2006-06-29 | Janssen Pharmaceutica N.V. | Tricyclic .delta.-opioid modulators |
| CA2594347A1 (en) * | 2005-01-06 | 2006-07-13 | Janssen Pharmaceutica N.V. | Tricyclic d-opioid modulators |
| AU2006258060A1 (en) * | 2005-06-09 | 2006-12-21 | Mallinckrodt Inc. | Method for separation and purification of naltrexone by preparative chromatography |
| CN101243079A (zh) * | 2005-06-16 | 2008-08-13 | 詹森药业有限公司 | 三环阿片调节剂 |
| KR20090057055A (ko) * | 2006-09-29 | 2009-06-03 | 니폰 조키 세야쿠 가부시키가이샤 | 옥세핀 유도체 |
| WO2008096360A2 (en) | 2007-02-06 | 2008-08-14 | Technion Research & Development Foundation Ltd. | Frictionless molecular rotary motors |
| CA2713293A1 (en) | 2008-01-30 | 2009-08-06 | Nippon Zoki Pharmaceutical Co., Ltd. | Piperidine derivative |
| PT2319840E (pt) * | 2008-08-01 | 2016-02-10 | Nippon Zoki Pharmaceutical Co | Derivado de aminopropilideno |
| IT1402691B1 (it) * | 2010-11-10 | 2013-09-13 | Lamberti Spa | Tioxantoni a bassa migrabilita' |
| CN110139852A (zh) | 2016-11-04 | 2019-08-16 | 奥克兰联合服务有限公司 | 三环杂环衍生物及其用途 |
| KR20190097245A (ko) * | 2016-12-28 | 2019-08-20 | 헨켈 아게 운트 코. 카게아아 | 티오크산톤 유도체 광개시제 |
| CN110483871A (zh) * | 2019-08-15 | 2019-11-22 | 陈全明 | 一种抗压耐磨的hdpe双壁波纹管 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2368006A (en) * | 1943-10-07 | 1945-01-23 | Searle & Co | Heterocyclic tertiary amines |
| FR1159125A (fr) * | 1953-03-27 | 1958-06-23 | Promonta Chem Fab | Procédé pour préparer des dérivés de la phényl-thiazine présentant comme substituant basique un noyau hétérocyclique contenant un atome d'azote |
| US2901478A (en) * | 1957-02-11 | 1959-08-25 | Promonta Chem Fab | Phenothiazine compounds |
| US3179665A (en) * | 1959-12-16 | 1965-04-20 | Wander Ag Dr A | 9-(n-ethyl and n-propyl piperidyl-3'-methyl)-thioxanthenes |
| DE1159954B (de) * | 1961-11-25 | 1963-12-27 | Boehringer & Soehne Gmbh | Verfahren zur Herstellung neuer 10-(Alkoxypiperidinopropyl)-phenthiazine und ihrer Salze |
| DE1670118A1 (de) | 1966-07-22 | 1970-11-05 | Boehringer Mannheim Gmbh | Verfahren zur Herstellung neuer Derivate des 6,11-Dihydro-dibenz[b,e]oxepins und ihrer Salze |
| US3470188A (en) * | 1967-01-05 | 1969-09-30 | Smithkline Corp | 9-cycloalkyl-lower alkyl-piperidylidene derivatives of xanthenes and thioxanthenes |
| NL6818027A (es) * | 1968-01-09 | 1969-07-11 | ||
| GB1250534A (es) | 1969-03-03 | 1971-10-20 | ||
| US3987042A (en) * | 1969-03-03 | 1976-10-19 | Claude Gueremy | Phenothiazine derivative |
| US3931232A (en) * | 1974-06-24 | 1976-01-06 | Smithkline Corporation | 3-Alkyl xanthene compounds |
| ZA756550B (en) * | 1974-11-06 | 1976-09-29 | Smithkline Corp | Pharmaceutical compositions and method of producing antipsychotic activity without extrapyramidal symptoms |
| US4086350A (en) * | 1974-11-06 | 1978-04-25 | Smithkline Corporation | Pharmaceutical compositions and method of producing anti-psychotic activity without extrapyramidal symptoms |
| US4285956A (en) * | 1978-05-12 | 1981-08-25 | Kefalas A/S | Xanthene and thioxanthene derivatives, compositions thereof and treatment therewith |
| US4356184A (en) * | 1980-06-04 | 1982-10-26 | G. D. Searle & Co. | Anti-allergic or antihypertensive 1-piperidinylmethyl benzenamines |
| US4666907A (en) * | 1983-10-05 | 1987-05-19 | Merck Frosst Canada, Inc. | Phenothiazine and derivatives and analogs and use as leukotriene biosynthesis inhibitors |
| US4777177A (en) * | 1984-10-19 | 1988-10-11 | Ciba-Geigy Corporation | Pesticidal thioxanthen-9-ylidenepiperidines |
| FR2689013B1 (fr) * | 1992-03-30 | 1995-05-05 | Rhone Poulenc Rorer Sa | Nouvelle application thérapeutique des dérivés de la phénothiazine. |
| ZA978792B (en) * | 1996-10-04 | 1998-04-06 | Novo Nordisk As | N-substituted azaheterocyclic compounds. |
| TW548271B (en) * | 1996-12-20 | 2003-08-21 | Astra Pharma Inc | Novel piperidine derivatives having an exocyclic double bond with analgesic effects |
| SE9604786D0 (sv) * | 1996-12-20 | 1996-12-20 | Astra Pharma Inc | New compounds |
| US6040318A (en) * | 1997-06-25 | 2000-03-21 | Novo Nordisk A/S | Tricycle substituted with azaheterocyclic carboxylic acids |
| EP0991633A1 (en) * | 1997-06-25 | 2000-04-12 | Novo Nordisk A/S | Novel heterocyclic compounds |
| JP4754068B2 (ja) | 1997-12-24 | 2011-08-24 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | δ−オピオイドレセプターに結合する４−［アリール（ピペリジン−４−イル）］アミノベンズアミド類 |
| CA2395471A1 (en) | 1999-12-22 | 2001-06-28 | Ortho-Mcneil Pharmaceutical, Inc. | 4-[aryl(8-azabicyclo[3.2.1]octan-3-yl)]aminobenzoic acid derivatives |
| US6552036B2 (en) | 2000-03-03 | 2003-04-22 | Ortho-Mcneil Pharmaceutical, Inc. | 3-(Diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives |
| AU2001249250A1 (en) | 2000-03-29 | 2001-10-08 | Research Triangle Institute | Selective ligands for the delta opioid receptor |
| SE0001207D0 (sv) * | 2000-04-04 | 2000-04-04 | Astrazeneca Canada Inc | Novel compounds |
| AU2002227135B2 (en) | 2000-10-31 | 2008-01-03 | Rensselaer Polytechnic Institute | 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents |
| WO2002048122A2 (en) | 2000-12-14 | 2002-06-20 | Ortho-Mcneil Pharmaceutical, Inc. | Benzamidine derivatives |
| SE0101765D0 (sv) * | 2001-05-18 | 2001-05-18 | Astrazeneca Ab | Novel compounds |
| US6601009B2 (en) * | 2001-07-12 | 2003-07-29 | Yahoo Inc | Method and system of automatic bandwidth detection |
| JP4337138B2 (ja) * | 2001-08-31 | 2009-09-30 | 味の素株式会社 | 新規ジアリールアルケン誘導体及び新規ジアリールアルカン誘導体 |
| SE0103313D0 (sv) * | 2001-10-03 | 2001-10-03 | Astrazeneca Ab | Novel compounds |
| JP2005529840A (ja) * | 2001-10-16 | 2005-10-06 | ヒプニオン， インコーポレイテッド | Ｃｎｓ標的モジュレータを使用するｃｎｓ障害の治療 |
| US7060711B2 (en) * | 2001-10-25 | 2006-06-13 | Biofrontera Bioscience Gmbh | Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist |
| EP1306376A1 (en) | 2001-10-25 | 2003-05-02 | Biofrontera Pharmaceuticals AG | Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist |
| EP1321169A1 (en) * | 2001-12-18 | 2003-06-25 | Biofrontera Pharmaceuticals AG | Combination of a serotonin receptor antagonist with a histidine decarboxylase inhibitor as a medicament |
| JP2005539076A (ja) | 2002-09-18 | 2005-12-22 | エフ エム シー コーポレーション | 殺虫用三環式誘導体 |
| US20040082612A1 (en) | 2002-10-15 | 2004-04-29 | Baxter Ellen W | Benzyl substituted (piperidin-4-yl)aminobenzamido derivatives |
| BRPI0409570A (pt) | 2003-04-15 | 2006-04-18 | Pfizer Prod Inc | derivados de 3-benzidrilideno-8-aza-biciclo[3.2.1]octano com atividade receptora de opióides |
| WO2005003131A1 (en) | 2003-06-27 | 2005-01-13 | Janssen Pharmaceutica N.V. | Tricyclic delta opioid modulators |
| CA2574768A1 (en) * | 2004-08-05 | 2006-02-05 | Janssen Pharmaceutica N.V. | Tricyclic delta-opioid modulators |
| CA2592464A1 (en) * | 2004-12-22 | 2006-06-29 | Janssen Pharmaceutica N.V. | Tricyclic .delta.-opioid modulators |
| BRPI0519198A2 (pt) * | 2004-12-22 | 2008-12-30 | Janssen Pharmaceutica Nv | moduladores de delta-opiàide tricÍclicos |
| AU2005319060A1 (en) * | 2004-12-22 | 2006-06-29 | Janssen Pharmaceutica N.V. | Tricyclic delta-opioid modulators |
| CA2594347A1 (en) | 2005-01-06 | 2006-07-13 | Janssen Pharmaceutica N.V. | Tricyclic d-opioid modulators |
| CN101243079A (zh) * | 2005-06-16 | 2008-08-13 | 詹森药业有限公司 | 三环阿片调节剂 |
-
2004
- 2004-06-22 WO PCT/US2004/019911 patent/WO2005003131A1/en not_active Ceased
- 2004-06-22 UA UAA200512736A patent/UA86024C2/ru unknown
- 2004-06-22 NZ NZ572901A patent/NZ572901A/en not_active IP Right Cessation
- 2004-06-22 AU AU2004253898A patent/AU2004253898A1/en not_active Abandoned
- 2004-06-22 BR BRPI0411998-3A patent/BRPI0411998A/pt not_active IP Right Cessation
- 2004-06-22 US US10/873,527 patent/US7589103B2/en active Active
- 2004-06-22 CN CNB2004800237098A patent/CN100513407C/zh not_active Expired - Fee Related
- 2004-06-22 EP EP04755822A patent/EP1644373A1/en not_active Withdrawn
- 2004-06-22 JP JP2006517517A patent/JP4810423B2/ja not_active Expired - Fee Related
- 2004-06-22 CA CA2530444A patent/CA2530444C/en not_active Expired - Fee Related
- 2004-06-22 KR KR1020057025145A patent/KR101132208B1/ko not_active Expired - Fee Related
- 2004-06-22 EA EA200501868A patent/EA015491B1/ru not_active IP Right Cessation
- 2004-06-28 AR ARP040102271A patent/AR044940A1/es not_active Application Discontinuation
- 2004-06-28 TW TW093118831A patent/TWI368510B/zh not_active IP Right Cessation
-
2005
- 2005-12-20 IL IL172713A patent/IL172713A0/en unknown
- 2005-12-27 EC EC2005006256A patent/ECSP056256A/es unknown
-
2006
- 2006-01-02 CR CR8166A patent/CR8166A/es not_active Application Discontinuation
- 2006-01-26 ZA ZA200600770A patent/ZA200600770B/en unknown
- 2006-01-27 NO NO20060446A patent/NO333611B1/no not_active IP Right Cessation
-
2009
- 2009-08-06 US US12/536,635 patent/US7982042B2/en not_active Expired - Fee Related
-
2011
- 2011-06-10 US US13/157,846 patent/US8106207B2/en not_active Expired - Fee Related
- 2011-12-22 US US13/334,374 patent/US8350041B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20090298867A1 (en) | 2009-12-03 |
| EA015491B1 (ru) | 2011-08-30 |
| EA200501868A1 (ru) | 2006-06-30 |
| JP2007516175A (ja) | 2007-06-21 |
| ZA200600770B (en) | 2007-05-30 |
| US8350041B2 (en) | 2013-01-08 |
| AU2004253898A1 (en) | 2005-01-13 |
| US8106207B2 (en) | 2012-01-31 |
| IL172713A0 (en) | 2006-04-10 |
| NO20060446L (no) | 2006-03-27 |
| CN1839135A (zh) | 2006-09-27 |
| EP1644373A1 (en) | 2006-04-12 |
| BRPI0411998A (pt) | 2006-09-05 |
| US20110245291A1 (en) | 2011-10-06 |
| UA86024C2 (ru) | 2009-03-25 |
| KR20060035645A (ko) | 2006-04-26 |
| KR101132208B1 (ko) | 2012-04-12 |
| CN100513407C (zh) | 2009-07-15 |
| US20050009860A1 (en) | 2005-01-13 |
| JP4810423B2 (ja) | 2011-11-09 |
| CA2530444A1 (en) | 2005-01-13 |
| TWI368510B (en) | 2012-07-21 |
| US20120095010A1 (en) | 2012-04-19 |
| US7982042B2 (en) | 2011-07-19 |
| CA2530444C (en) | 2012-03-13 |
| ECSP056256A (es) | 2006-04-19 |
| CR8166A (es) | 2009-01-16 |
| NZ572901A (en) | 2010-06-25 |
| TW200528105A (en) | 2005-09-01 |
| HK1097532A1 (zh) | 2007-06-29 |
| US7589103B2 (en) | 2009-09-15 |
| NO333611B1 (no) | 2013-07-22 |
| WO2005003131A1 (en) | 2005-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR044940A1 (es) | Compuestos heterociclicos y su uso como moduladores de gamma opioides | |
| RU2018121834A (ru) | Новое соединение бифенила или его соль | |
| RU2005122901A (ru) | Производные пиридино [2,3-] пиримидина в качестве селективных ингибиторов kdr и fgfr | |
| AR060537A1 (es) | 1,2,4-triazoles trisustituidos | |
| AR062937A1 (es) | Compuestos que modulan el receptor cb2 | |
| CO5570669A2 (es) | Pirazolopirimidinas como agentes terapeuticos | |
| CO5251463A1 (es) | Compuestos heterociclicos y composicion farmaceutica que coniene dichos compuestos | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| BRPI0407082C1 (pt) | composto n-(4-(1-(2,6-difluorobenzil)-5-((dimetilamino)metil)-3-(6-metóxi-3-piridazinil)-2,4-dioxo-1,2,3,4-tetraidrotieno[2,3-d]pirimidina-6-il)fenil)-n-metoxiuréia, ou um sal do mesmo, produto farmacêutico, e, uso do composto | |
| CO5700774A2 (es) | Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa-1 | |
| AR041303A1 (es) | Compuestos de piperidinil-imidazopiridina n-sustituidos como moduladores del receptor 5-ht4" | |
| HRP20020926B1 (en) | Arylmethylamine derivatives for use as tryptase inhibitors | |
| EA200970510A1 (ru) | Гетеромоноциклическое соединение и его применение | |
| AR038536A1 (es) | N-aril-2-oxazolidinona-5- carboxamidas y sus derivados | |
| JP2003500404A5 (es) | ||
| NZ603896A (en) | 3-amino-5,6-dihydro-1h-pyrazin-2-one derivatives useful for the treatement of alzheimer's disease and other forms of dementia | |
| RU2019143759A (ru) | Новое соединение бифенила или его соль | |
| NO20060670L (no) | N3-substituerte imidazopyridin C-kit inhibitorer | |
| WO2008007123A3 (en) | Pharmaceutical compounds | |
| EA201190119A1 (ru) | ПРОИЗВОДНЫЕ ТРИАЗОЛОПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ МАР-КИНАЗЫ p38 | |
| MX2007007428A (es) | Compuestos heterociclicos, antagonistas de ccr2b. | |
| RU2006109004A (ru) | 7-аминоалкилиденилгетероциклические хинолоны и нафтиридоны | |
| JP2006523698A5 (es) | ||
| RU99109032A (ru) | Производные 2-цианоиминоимидазола, ингибирующие pde iv | |
| AR057374A1 (es) | Moduladres opioides triciclicos y composiciones farmaceuticas y veterinarias |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |